Eris Lifesciences · NSE: ERIS · BSE: 540596
Q1 FY20 results · Apr–Jun 2019
Eris Lifesciences reported revenue from operations of ₹274.30 crore (up 9.4% from Q1 FY19) and net profit of ₹84.06 crore (up 17.5% from Q1 FY19) for Q1 FY20 (Apr–Jun 2019), on a consolidated basis.
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 274.30 | 250.76 | +9.4% | 214.82 | +27.7% |
| Other income | 2.83 | 3.52 | −19.8% | 11.73 | −75.9% |
| Total income | 277.13 | 254.28 | +9.0% | 226.55 | +22.3% |
| Profit before tax | 94.92 | 77.69 | +22.2% | 58.24 | +63.0% |
| Net profit for the period | 84.06 | 71.56 | +17.5% | 53.88 | +56.0% |
| Attributable to shareholders of the company | 84.05 | 71.25 | +18.0% | 54.09 | +55.4% |
| EPS, basic (₹) | 6.11 | 5.18 | +18.0% | 3.93 | +55.5% |
| Net margin (%) | 30.6 | 28.5 | 25.1 |
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 262.33 | 226.50 | +15.8% | 198.43 | +32.2% |
| Other income | 2.72 | 4.51 | −39.7% | 11.60 | −76.6% |
| Total income | 265.04 | 231.00 | +14.7% | 210.03 | +26.2% |
| Profit before tax | 92.04 | 75.42 | +22.0% | 59.10 | +55.7% |
| Net profit for the period | 81.96 | 70.10 | +16.9% | 52.42 | +56.4% |
| EPS, basic (₹) | 5.96 | 5.10 | +16.9% | 3.81 | +56.4% |
| Net margin (%) | 31.2 | 31.0 | 26.4 |
Consolidated
- Filed with BSE
- 27 Jul 2019, 15:53 IST
- Board meeting
- 27 Jul 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Jul 2019, 15:53 IST
- Board meeting
- 27 Jul 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE